KR20220168723A - Health functional foods that prevent hyperlipidemia - Google Patents

Health functional foods that prevent hyperlipidemia Download PDF

Info

Publication number
KR20220168723A
KR20220168723A KR1020210078578A KR20210078578A KR20220168723A KR 20220168723 A KR20220168723 A KR 20220168723A KR 1020210078578 A KR1020210078578 A KR 1020210078578A KR 20210078578 A KR20210078578 A KR 20210078578A KR 20220168723 A KR20220168723 A KR 20220168723A
Authority
KR
South Korea
Prior art keywords
extract powder
hyperlipidemia
weight
mushroom
hours
Prior art date
Application number
KR1020210078578A
Other languages
Korean (ko)
Inventor
김수연
Original Assignee
만보식품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 만보식품 주식회사 filed Critical 만보식품 주식회사
Priority to KR1020210078578A priority Critical patent/KR20220168723A/en
Publication of KR20220168723A publication Critical patent/KR20220168723A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/40Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
    • A23L3/44Freeze-drying
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00Edible extracts or preparations of fungi; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/10Drying, dehydrating
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/14Extraction
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/26Homogenisation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a health functional food composition for hyperlipidemia having a hyperlipidemia-inhibiting effect and a method for manufacturing the same. More specifically, the present invention relates to: an autoclave extraction method that can extract the polysaccharide of Coriolus versicolor, which is a physiologically active substance, from Coriolus versicolor (fruiting body) in high yield; a health functional food composition for hyperlipidemia with novel composition which contains extract powder of Salvia miltiorrhiza, Pueraria lobata var. thomsonii, Cnidium officinale, Carthamus tinctorius seeds, and Crataegus pinnatifida to a Coriolus versicolor extraction powder containing the polysaccharide of Coriolus versicolor obtained from the same; and a method for manufacturing the same.

Description

고지혈증을 예방하는 건강기능식품{Health functional foods that prevent hyperlipidemia}Health functional foods that prevent hyperlipidemia}

본 발명은 고지혈증 억제효과가 있는 천연물의 조성물 및 그의 제조방법에 관한 것이다. 더욱 상세하게는 운지버섯(자실체)으로부터 생리활성물질인 운지버섯다당체를 고수율로 추출 할 수 있는 오토 클레이브 추출법과 그것으로부터 얻은 운지버섯다당체를 함유한 운지버섯추출물 분말에 단삼, 갈근, 천궁, 홍화씨 및 산사자추출물 분말을 함유시킨 새로운 조성의 고지혈증 억제효과가 있는 고지혈증용 건강기능식품 조성물 및 그의 제조방법에 관한 것이다.The present invention relates to a natural composition having hyperlipidemia-inhibiting effects and a method for preparing the same. More specifically, the autoclave extraction method that can extract the polysaccharide of the mushroom, which is a physiologically active substance, from the mushroom (fruiting body) in high yield, and the mushroom extract powder containing the polysaccharide of the mushroom obtained from it. And it relates to a health functional food composition for hyperlipidemia containing hawthorn extract powder having a hyperlipidemia inhibitory effect of a new composition and a manufacturing method thereof.

생활습관의 변화 특히 식생활의 서구화 등으로 섭취지방분의 증가 및 운동부족 등으로 고혈압, 당뇨, 동맥경화증,뇌졸중, 비만, 고지혈증, 심장병등의 질환이 증가되고 있다. 이를 흔히 성인병이라고 불러왔는데, 최근에는 이들을생활 습관증이라고도 부르고 있다.Diseases such as high blood pressure, diabetes, arteriosclerosis, stroke, obesity, hyperlipidemia, and heart disease are increasing due to changes in lifestyle, especially westernization of diet, increase in fat intake and lack of exercise. This is often called an adult disease, but recently it is also called lifestyle disease.

과거에는 나이가 들면서 흔하게 생기는 노인질환으로 인식하였으나, 최근에는 이러한 질환들이 점점 젊은 나이에흔하게 나타나며, 심지어는 소아 및 청소년기에도 나타나기 때문에 더 이상 성인병이란 용어는 부적절하다고 생각되며,In the past, it was recognized as a geriatric disease that commonly occurs with age, but recently, these diseases are increasingly common at a young age, and even appear in children and adolescents, so the term adult disease is no longer considered appropriate.

특히 심혈관계 질환은 서구는 물론 전세계에서 가장 흔한 사망원인을 차지하고 있으며, 이들의 주된 발병기전은 동맥경화증으로 알려져 있다. 고혈압, 흡연, 비만 및 고지혈증 등이 동맥경화증을 야기시키는 위험인자인데 이중 고지 혈증(高脂血症: hyperlipidemia)은 중성 지방과 혈중 콜레스테롤 등의 지방대사가 제대로 이루어지지 않아 혈액 중에 지방량이 많아진 상태로 동맥경화성 질환인 허혈성 심장질환이나 뇌혈관장애에 대한 중요한 위험인자가 되고 있다.In particular, cardiovascular diseases account for the most common cause of death in the world as well as in the West, and their main pathogenesis is known to be atherosclerosis. High blood pressure, smoking, obesity, and hyperlipidemia are risk factors that cause atherosclerosis. It has become an important risk factor for ischemic heart disease or cerebrovascular disease, which are atherosclerotic diseases.

고지혈증의 한방적인 원인으로는 1)혈액중에 수(水), 습(濕), 담(痰), 탁(濁), 어혈(瘀血)과 같은 이물질로 인한 경우와, 2)비장, 간장, 심장의 기능저하로 습(濕)과 담(痰)이 정체되어 일어나는 경우, 또는 3)화병(스트레스)으로 기(氣)가 울체되어 혈관에 노폐물이 쌓여서 생기는 것으로, 간에서 분해작업을 하는 동안 지방독이 생겨 간세포에 서서히쌓여 지방변성을 일으켜 발병하는 것으로 알려져 있다.따라서, 한방에서는 고지혈증을 지방과 노폐물이 혈관과 간에 쌓여서 생긴 질환으로 해석하고 있다.The oriental causes of hyperlipidemia are 1) foreign substances such as water, damp, phlegm, turbidity, and blood clots in the blood, and 2) spleen, liver, It is caused by stagnation of dampness and phlegm due to a decrease in heart function, or 3) stagnation of energy due to hwabyung (stress) and accumulation of wastes in the blood vessels. During decomposition in the liver It is known that lipotoxicity occurs and gradually accumulates in liver cells, causing fatty degeneration. Therefore, in oriental medicine, hyperlipidemia is interpreted as a disease caused by accumulation of fat and waste products in the blood vessels and liver.

이에 본 발명자는 새로운 고지혈증 천연약재를 함유한 건강기능식품 조성물을 개발하기 위한 일환으로, 한의학적측면에서 고지혈증과 관련이 있는 질환에 이용되고 있는 천연약재를 선별하고, 보다 우수한 고지혈증 천연약물 방제(처방조성)를 구성하기 위하여 임상뿐만 아니라 한의학 고전에 기록되어 있는 방제(처방조성)를 기본으로 하여이를 토대로 수종의 한약을 가미하거나 가감하여 새로운 조성을 구성하여, 새로운 조성물이 고지혈증에 미치는 영향을 연구하고자, 고지방 식이(High lipid diet) 혼합사료에 의한 고지혈증을 유발시킨 흰쥐에 새로운 조성물을 투여하여 흰쥐의 혈청중 트란스아미나제(trasaminase) 활성도인 GOT, GPT치와 총 콜레스테롤(total cholesterol), 혈청중 트리글리세라이드(Triglyceride), 고밀도 지단백 콜레스테롤(HDL-Cholesterol)의 시험을 실시하고,이에 대한 연구를 거듭한 결과, 새로운 조성물이 고지혈증에 효과를 가지고 있음을 발견하여 본 발명을 완성하였다.Accordingly, the present inventors, as part of developing a health functional food composition containing new hyperlipidemia natural medicines, selected natural medicines used for diseases related to hyperlipidemia in oriental medicine, and improved hyperlipidemia natural medicine control (prescription composition). ) In order to construct a new composition by adding or subtracting several kinds of herbal medicine based on the control (prescription composition) recorded in the clinical as well as the classics of oriental medicine, to study the effect of the new composition on hyperlipidemia, high fat By administering the new composition to rats induced hyperlipidemia by high lipid diet mixed feed, the serum transaminase activity, GOT and GPT levels, total cholesterol, and serum triglycerides ( Triglyceride) and high-density lipoprotein cholesterol (HDL-Cholesterol) were tested, and as a result of repeated research on this, it was found that the new composition had an effect on hyperlipidemia, and the present invention was completed.

1) 운지버섯(자실체)을 110~130 ℃에서 2-3 시간동안 물, 에탄올 또는 이들의 혼합용액 중에서 선택한 1종의 용매로 오토 클레이브 추출기에서 추출하고, 여과 농축한 다음 동결 또는 분무건조시킨 운지버섯추출물분말 35.0∼55.0중량 %와 2) 단삼, 갈근, 천궁, 홍화씨 및 산사자를 110~130 ℃에서 2-3 시간동안 각각 별도로 물, 에탄올 또는 이들의 혼합용액 중에서 선택한 1종의 용매로 오토 클레이브 추출기에서 추출하고, 여과 농축한 다음 동결 또는 분무건조시킨 단삼추출물분말 10.0∼30.0 중량%, 갈근추출물분말 10.0∼20.0 중량%, 천궁추출물분말 1.0∼10.0 중량%, 홍화씨추출물분말 1.0∼10.0 중량%, 산사자추출물분말 5.0∼15.0 중량%와, 3) 제제학적으로 허용 가능한 1종이상의 담체를 혼합, 균질화 시켜 고지혈증용 건강 기능 식품조성물을 제조하는 방법.1) Fingering mushroom (fruiting body) is extracted in an autoclave extractor with one solvent selected from water, ethanol or a mixture thereof at 110-130 ° C for 2-3 hours, concentrated by filtration, and then frozen or spray-dried. Mushroom extract powder 35.0 ~ 55.0% by weight and 2) Danshen, Ginger root, cnidium, safflower seed, and mountain lion at 110 ~ 130 ℃ for 2-3 hours, respectively, separately autoclaved with one solvent selected from water, ethanol or a mixture thereof Extracted in an extractor, concentrated by filtration, and then frozen or spray-dried, 10.0-30.0% by weight of Danshen extract powder, 10.0-20.0% by weight of radish root extract powder, 1.0-10.0% by weight of cnidium extract powder, 1.0-10.0% by weight of safflower seed extract powder, A method for preparing a health functional food composition for hyperlipidemia by mixing and homogenizing 5.0 to 15.0% by weight of hawthorn extract powder and 3) one or more pharmaceutically acceptable carriers.

이상과 같은 실험결과로부터, 고지방 식이(High lipid diet)혼합사료를 투여하여 유발시킨 고지혈증에 대한 새로운조성물의 투여가 혈청중 총 콜레스테롤 (Total Cholesterol)함량, 혈청중 트리글리세라이드(Triglyceride)함량, 고밀도 지단백 콜레스테롤(HDL-Cholesterol)함량에 대해 현저한 저하작용을 나타내었다.따라서, 본 발명에 따른 고지혈증용 건강기능식품 조성물은 고지혈증개선에 탁월한 효과가 예상된다.From the above experimental results, administration of a new composition for hyperlipidemia induced by administering a high-fat diet mixed feed resulted in total cholesterol content in serum, triglyceride content in serum, high-density lipoprotein It showed a significant lowering effect on cholesterol (HDL-Cholesterol) content. Therefore, the health functional food composition for hyperlipidemia according to the present invention is expected to have an excellent effect on improving hyperlipidemia.

본 발명의 고지혈증용 건강기능식품 및 그의 제조방법에 대하여 설명하면, 본 발명의 조성물은 운지버섯추출물분말35.0∼55.0 중량% , 단삼추출물분말 10.0∼30.0 중량%, 갈근추출물분말 10.0∼20.0 중량%, 천궁추출물분말1.0∼10.0 중량%, 홍화씨추출물분말 1.0∼10.0 중량%, 산사자추출물분말 5.0∼150 중량%로 구성된 고지혈증용건강기능식품 조성물이고, 그의 제조방법을 요약하면, 1) 운지버섯(자실체)을 110~130 ℃에서 2-3 시간동안 물,에탄올 또는 이들의 혼합용액 중에서 선택한 1종의 용매로 오토 클레이브 추출기에서 추출하고, 여과 농축한 다음동결 또는 분무건조시킨 운지버섯추출물분말 35.0∼55.0 중량%와, 2) 단삼, 갈근, 천궁, 홍화씨 및 산사자를110~130 ℃에서 2-3 시간동안 각각 별도로 물, 에탄올 또는 이들의 혼합용액 중에서 선택한 1종의 용매로 오토 클레이브 추출기에서 추출하고, 여과 농축한 다음 동결 또는 분무건조시킨 단삼추출물분말 10.0∼30.0 중량%, 갈근추출물분말 10.0∼20.0 중량%, 천궁추출물분말 1.0∼10.0 중량%, 홍화씨추출물분말 1.0∼10.0 중량%, 산사자추출물분말 5.0∼15.0 중량%와, 3) 제제학적으로 허용 가능한 1종이상의 담체를 혼합, 균질화 시켜 고지혈증용 건강기능식품을 제조하는 방법이다.Referring to the health functional food for hyperlipidemia of the present invention and its manufacturing method, the composition of the present invention contains 35.0 to 55.0% by weight of mushroom extract powder, 10.0 to 30.0% by weight of Danshen extract powder, 10.0 to 20.0% by weight of algae root extract powder, It is a health functional food composition for hyperlipidemia composed of 1.0 to 10.0% by weight of cnidium extract powder, 1.0 to 10.0% by weight of safflower seed extract powder, and 5.0 to 150% by weight of hawthorn extract powder. was extracted in an autoclave extractor with one solvent selected from water, ethanol or a mixture thereof at 110-130 ° C for 2-3 hours, concentrated by filtration, and then freeze-dried or spray-dried. % and, 2) Danshen, root, cnidium, safflower, and hawthorn were separately extracted at 110 to 130 ° C for 2-3 hours in an autoclave extractor with one solvent selected from water, ethanol, or a mixture thereof, and filtered Concentrated and then frozen or spray-dried Danshen extract powder 10.0-30.0% by weight, radish root extract powder 10.0-20.0% by weight, cnidium extract powder 1.0-10.0% by weight, safflower seed extract powder 1.0-10.0% by weight, hawthorn extract powder 5.0-15.0 % by weight and 3) a method for preparing a health functional food for hyperlipidemia by mixing and homogenizing one or more pharmaceutically acceptable carriers.

운지버섯(Coriolus versicolor (L.ex Fr.) Quel.)은 민주름버섯목 구멍장이버섯과(Polyporaceae)의 버섯이다. 마치 구름처럼 뭉쳐서 난다고하여 한자로 구름운(雲), 버섯 지(芝), 즉 운지(雲芝)라고 부른다.Coriolus versicolor (L.ex Fr.) Quel. is a mushroom of the Polyporaceae family. Because they come together like clouds, they are called Cloud Cloud (Cloud) and Mushroom Ji (芝), that is, Unji (Cloud 芝) in Chinese characters.

한국등 전 세계적으로 침엽수, 활엽수의 고목 또는 그루터기등에 수십 내지 수백 개가 군생하고 백색부후(白色腐朽)를 일으키며, 1년중에 생성된다. 균모는 얇고 단단한 가죽질이며, 반원형, 나비 1∼5 cm, 두께 1∼2 mm이고, 1년생이다.Dozens to hundreds of them grow in groups on dead trees or stumps of conifers and broad-leaved trees around the world, including Korea, and cause white rot, and are generated during the year. Mycobacteria are thin, hard leathery, semicircular, 1-5 cm wide, 1-2 mm thick, annual.

표면은 흑색에서 남흑색이고 회색, 황갈색, 암갈색, 흑갈색, 흑색을 띄는 구름무늬를 나타내고, 짧은 털로 덮여 있다.채취시기는 여름, 가을철에 따서 햇볕에 쬐어 말린다.맛은 약간 달고 차다. 주요성분은 코리오란(coriolan), 크레스틴(Krestin), ATSO, 다당체이다.효능 효과는 거습(去濕), 항암, B형간염, 천연성 간염, 만성활동성 간염, 만성 기관지염, 간암의 예방 및 치료, 소화기계 암, 유방암, 폐암, 항종양(Sarcoma 180/마우스, 억제율 100%), 보체활성, 면역효과, 콜레스테롤저하, 혈당증가억제효과가 있다.The surface is black to indigo black, with gray, tan, dark brown, dark brown, and black cloud patterns, covered with short hairs. Harvest season is summer and autumn, and dried in the sun. The taste is slightly sweet and cold. The main components are coriolan, Krestin, ATSO, and polysaccharides. Efficacy effects include dampening, anti-cancer, hepatitis B, natural hepatitis, chronic active hepatitis, chronic bronchitis, prevention of liver cancer and Treatment, digestive system cancer, breast cancer, lung cancer, anti-tumor (Sarcoma 180/mouse, inhibition rate 100%), complement activity, immune effect, cholesterol lowering, blood sugar increase suppression effect.

우리나라 거의 모든 산에 다 있어 발견하기가 쉽고 채취하여 말렸다가 10 ~20 그램을 물로 달여서 보리차처럼 음용할 수 있다.여러 종류의 식물체 중에서 특히 버섯은 옛날부터 세계의 각 민족들 사이에 영양소 보급원으로 먹거나 한방약 또는민간약으로 쓰이면서, 약리작용을 갖고 있는 것으로 알려져 있다. 우리나라에서 고등 담자균류인 약용버섯과 식용버섯등 여러종류의 버섯이 생육하고 있으나, 버섯추출물로써의 생리활성에 대한 연구는 많이 부족한 실정이다.본 발명자들은 생리활성이 높은 운지버섯추출물 분말을 제조하기 위하여 추출방법으로서 오토 클레이브 추출법을이용함으로써 종래의 단순한 환류 추출법보다 우수한 추출 효율로 운지버섯의 활성성분인 운지버섯다당체를 추출할 수 있었고, 또한 운지버섯 중의 활성성분을 손실없이 그대로 유지하면서 높은 안정성을 가진 운지버섯추출물분말을 제조할 수 있었으며, 이 운지버섯추출물분말을 함유한 새로운 조성물을 제조하였다.본 발명의 한가지 특징에 의하면, 운지버섯의 추출 수단에 있어서 추출용매로는 물, 에탄올 또는 이들의 혼합용액중에서 선택한 1종의 추출용매로 사용할 수 있고, 추출 방법은 오토 클레이브 추출법을 이용한다. 오토 클레이브 추출은 110~130 ℃에서 2∼3 시간동안 추출하는데, 바람직하게는 2 시간 추출한다. 추출후 50 μm의 필터로 여과하여 1/10 량으로 농축한 후 3 배량의 에탄올을 가하고 12 시간 동안 방치한다. 침전물이 형성된 후여과하여 침전물을 수거한 다음 비스킹 튜브(Visking tube)를 사용하여 흐르는 물에 48 시간 동안 투석하고, 동결건조 또는 분무 건조 처리하여 운지버섯추출물분말을 제조한다.It is located in almost every mountain in Korea, so it is easy to find it, and after collecting and drying it, you can boil 10 to 20 grams of it in water and drink it like barley tea. It is known to have pharmacological effects while being eaten or used as herbal medicine or folk medicine. Various types of mushrooms, such as medicinal mushrooms and edible mushrooms, which are higher basidiomycetes, are growing in Korea, but research on the physiological activity as a mushroom extract is lacking. By using the autoclave extraction method as an extraction method, it was possible to extract the polysaccharide of the mushroom fingernails, which is the active ingredient of the mushroom fingernails, with higher extraction efficiency than the conventional simple reflux extraction method, It was possible to prepare a mushroom fingernail extract powder, and a new composition containing the fingernail mushroom extract powder was prepared. According to one feature of the present invention, in the method for extracting a fingernail mushroom, the extraction solvent is water, ethanol, or a mixture thereof. It can be used as one type of extraction solvent selected from the solution, and the extraction method uses the autoclave extraction method. Autoclave extraction is performed at 110 to 130 ° C. for 2 to 3 hours, preferably 2 hours. After extraction, the mixture was filtered through a 50 μm filter, concentrated to 1/10 the amount, and then 3 times the amount of ethanol was added and allowed to stand for 12 hours. After the precipitate is formed, the precipitate is collected by filtration, then dialyzed in running water for 48 hours using a Visking tube, and freeze-dried or spray-dried to prepare a mushroom extract powder.

기타 나머지 식물생약인 단삼, 갈근, 천궁, 홍화씨 및산사자추출물분말에 대하여 설명한다.단삼추출물분말은 꿀풀과(Labiatae)에 속하는 단삼(Salvia milltiorrhiza Bunge)의 뿌리를 추출하여 얻은 건조추출물로, 탄신온(tanshinone), 크리프토탄신온(cryptotanshinone)등을 함유하고 있으며, 예부터 강장, 통경등으로 쓰여왔다.갈근추출물분말은 콩과(Leguminosae)에 속하는 칡(Pueraria Thunbergiana Bentham)의 코르크피를 제거하고 말린 뿌리를 추출하여 얻은 건조추출물로, 다이드제인(daidzein), 푸에라린(puerarin)등을 함유하고 있으며, 예부터발한, 해열약으로 사용되어 왔다.Other herbal medicines, such as Danshen, Gale root, Cnidium, Safflower seed, and Hawthorn extract powder, are described. Danshen extract powder is a dried extract obtained by extracting the root of Salvia milltiorrhiza Bunge belonging to the Lamiaceae family (Labiatae). It contains tanshinone and cryptotanshinone, and has been used as a tonic and tonic since ancient times. It is a dried extract obtained by extracting the root, and contains daidzein and puerarin, etc., and has been used as an antiperspirant and fever reducer since ancient times.

천궁추출물분말은 미나리과(Umbelliferae)에 속하는 천궁(Cnidium officinale Makino)의 근경(Rhizoma)를 추출하여 얻은 건조추출물로, 크니디라이드 (cnidilide), 네오크니디라이드(neocnidilide)등을 함유하고 있으며, 예로부터 보혈, 강장, 진통등으로 쓰여왔다.Cnidium officinale Makino (Cnidium officinale Makino) belonging to the Apiaceae (Umbelliferae) Cnidium officinale Makino dried extract obtained by extracting the dried extract, contains cnidilide, neocnidilide, etc. It has been used for blood, tonic, and pain relief.

홍화씨추출물분말은 국화과(Compositae)에 속하는 잇꽃(Carthamus tinctorius L.)의 씨를 추출하여 얻은 건조추출물로, 리놀산(linoleic acid)등을 함유하고 있으며, 예로부터 동맥경화 치료와 예방 등으로 쓰여왔다.사자추출물분말은 장미과(Rosaceae)에 속하는 산사나무(Crataegus pinnatifida Bunge)의 열매를 추출하여 얻은 건조추출물로, 우르소릭산(ursolic acid)등을 함유하고 있으며, 예로부터 건위, 소화, 정장, 장카타르에 사용되어왔다.Safflower seed extract powder is a dried extract obtained by extracting the seeds of safflower (Carthamus tinctorius L.) belonging to the Asteraceae family (Compositae). It contains linoleic acid and has been used for the treatment and prevention of arteriosclerosis since ancient times. The extract powder is a dried extract obtained by extracting the fruits of Crataegus pinnatifida Bunge belonging to the Rosaceae family, and contains ursolic acid. has been used

본 발명의 다른 한가지 특징에 의하면, 운지버섯을 제외한 새로운 조성의 생약의 추출수단에 있어서 추출용매로는물, 에탄올 또는 이들의 혼합용액 중에서선택한 1종의 추출용매로 사용할 수 있고, 추출방법은 오토 클레이브 추출법을 이용한다.According to another feature of the present invention, in the extracting means of crude drugs of a new composition except for fingernail mushrooms, one type of extraction solvent selected from water, ethanol or a mixture thereof can be used as an extraction solvent, and the extraction method is an autoclave use the extraction method.

오토 클레이브 추출은 110~130 ℃에서 2∼3 시간동안 추출하는데, 바람직하게는 2 시간 추출한다. 추출후 50 μm의 필터로 여과하고 동결 건조 또는 분무 건조 처리하여 각각의 생약 추출물분말을 별도로 제조한다.동결 건조에는 시료를 먼저 -30∼-50 ℃로 급속히 동결시키고, 이 동결물을 진공도 1∼0.1 mmHg 정도의 진공으로 유지하면서 48∼72 시간 처리하여 얻은 동결 건조물을 200 메쉬로 분쇄한다.Autoclave extraction is performed at 110 to 130 ° C. for 2 to 3 hours, preferably 2 hours. After extraction, it is filtered through a 50 μm filter, and freeze-dried or spray-dried to prepare each crude drug extract powder separately. In freeze-drying, the sample is first rapidly frozen at -30 to -50 ° C, and the frozen product is frozen at a vacuum degree of 1 to 50 ° C. The freeze-dried product obtained by treatment for 48 to 72 hours while maintaining a vacuum of about 0.1 mmHg is pulverized into a 200 mesh.

분무 건조시에는 상온형 분무 건조기에서 공지의 방법으로 처리한다.In the case of spray drying, it is treated by a known method in a room temperature type spray dryer.

본 발명에 따른 고지혈증용 건강기능식품 조성물을 구성하는 운지버섯추출물분말의 조성비는 전체 생약중량에 대해 35.0∼55.0 중량%, 바람직하게는 40.0∼50.0 중량%이다. 만약 35.0 중량% 이하에서는 고지혈증에 대한 기대에 따른 기능성을 발휘하지 못하여 바람직하지 못하고, 55.0 중량% 이상 사용시에는 캅셀제조시 충진공정에서 인습작용으로 고형화 현상이 발생되어 또한 바람직하지 못하다.The composition ratio of the mushroom extract powder constituting the health functional food composition for hyperlipidemia according to the present invention is 35.0 to 55.0% by weight, preferably 40.0 to 50.0% by weight, based on the total weight of the herbal medicine. If it is less than 35.0% by weight, it is not preferable because it does not exhibit the functionality expected for hyperlipidemia, and if it is used more than 55.0% by weight, a solidification phenomenon occurs due to the action of moisture in the filling process during capsule manufacturing, which is also undesirable.

단삼추출물분말의 조성비는 전체 생약중량에 대해 10.0∼30.0 중량%, 바람직하게는 15.0∼25.0 중량%이다. 만약15.0 중량% 이하에서는 고지혈증에 대한 기대에 따른기능성을 발휘하지 못하여 바람직하지 못하고, 30.0 중량%이상 사용시에는 캅셀제조시 혼합공정에서 인습작용으로 고형화 현상이 발생되어 또한 바람직하지 못하다.갈근추출물분말의 조성비는 전체 생약중량에 대해 10.0∼20.0 중량%, 바람직하게는 12.5∼17.5 중량%이다. 만약10.0 중량% 이하에서는 고지혈증에 대한 기대에 따른 기능성을 발휘하지 못하여 바람직하지 못하고, 20.0 중량%이상 사용시에는 캅셀제조시 과립공정에서 인습작용으로 고형화 현상이 발생되어 또한 바람직하지 못하다.The composition ratio of the Danshen extract powder is 10.0 to 30.0% by weight, preferably 15.0 to 25.0% by weight, based on the total weight of the crude drug. If it is less than 15.0% by weight, it is undesirable because it does not exhibit the functionality expected for hyperlipidemia, and if it is used more than 30.0% by weight, solidification occurs due to the action of moisture in the mixing process during capsule manufacturing, which is also undesirable. The composition ratio is 10.0 to 20.0% by weight, preferably 12.5 to 17.5% by weight, based on the total weight of the herbal medicine. If it is less than 10.0% by weight, it is not preferable because it does not exhibit the functionality expected for hyperlipidemia, and if it is used more than 20.0% by weight, a solidification phenomenon occurs due to the action of moisture in the granulation process during capsule manufacturing, which is also undesirable.

천궁추출물분말 및 홍화씨추출물분말의 조성비는 전체 생약중량에 대해 각각 1.0∼10.0 중량%을 함유하는 것이 바람직한데, 1.0 중량% 이하에서는 고지혈증에 대한 기대에 따른 기능성을 발휘하지 못하여 바람직하지 못하고, 10.0중량% 이상 사용시에는 캅셀제조시 과립공정에서 결합력의 저하로 부서지는 현상이 발생되어 또한 바람직하지 못하다.The composition ratio of cnidium extract powder and safflower seed extract powder is preferably 1.0 to 10.0% by weight, respectively, based on the total weight of the herbal medicine. When using more than %, a phenomenon of breaking occurs due to a decrease in bonding strength in the granulation process during capsule manufacturing, which is also undesirable.

산사자추출물분말의 조성비는 전체 생약중량에 대해 5.0∼15.0 중량%, 바람직하게는 8.0∼12.0 중량%이다. 만약5.0 중량% 이하에서는 고지혈증에 대한 기대에 따른 기능성을 발휘하지 못하여 바람직하지 못하고, 15.0 중량% 이상 사용시에는 캅셀제조시 균질화공정에서 인습작용으로 고형화 현상이 발생되어 또한 바람직하지 못하다.본 발명의 새로운조성물에 제제학적으로 허용 기능한 1종이상의 담체와 혼합,균질화시켜 제제화 할 수 있으며, 전분, 유당, 스테비오사이드 등의 적당한 부형제, 안정화제, 감미제, pH 조정제, 현탁화제, 향료 등을 함유한 과립제,정제, 캅셀제, 환제, 액제로 경구 복용할 수 있다.The composition ratio of hawthorn extract powder is 5.0 to 15.0% by weight, preferably 8.0 to 12.0% by weight, based on the total weight of the crude drug. If it is less than 5.0% by weight, it is not preferable because it does not exhibit the functionality expected for hyperlipidemia, and if it is used more than 15.0% by weight, a solidification phenomenon occurs due to the action of moisture in the homogenization process during capsule manufacturing, which is also undesirable. Granules that can be formulated by mixing and homogenizing one or more pharmaceutically acceptable carriers in the composition, and containing appropriate excipients such as starch, lactose, and stevioside, stabilizers, sweeteners, pH adjusters, suspending agents, flavorings, etc. It can be taken orally in the form of tablets, capsules, pills, and liquids.

본 발명에서 제공하는 캅셀제는 통상의 제조방법에 따른다. 즉, 본 발명의 캅셀제는 운지버섯(자실체)을 정밀히 달아 오토 클레이브 추출기에 넣고 추출한 다음, 여과하고 냉동건조하여 운지버섯추출물분말을 만들고, 따로 단삼, 갈근, 천궁, 홍화씨, 산사자를 정밀히 달아 각각의 생약을 별도의 오토 클레이브 추출기에 넣고 추출한 다음, 여과하고 냉동건조하여, 각각의 추출물분말을 만든다.운지버섯추출물분말과 각각의 추출물분말을 가지고 혼합, 균질화하고 과립화하여 캅셀에 충진하여 캅셀제를 만든다.The capsules provided in the present invention follow conventional manufacturing methods. That is, the capsule of the present invention is precisely weighed and put in an autoclave extractor, extracted, filtered and freeze-dried to make a powdered mushroom extract, and separately weighs dandelion, root, cnidium, safflower seed, and mountain lion precisely, respectively. Herbal medicines are put into a separate autoclave extractor, extracted, filtered, and freeze-dried to make each extract powder. Mix, homogenize, and granulate the extract powder of the mushroom extract and each extract powder, and fill the capsules to make capsules. .

상기와 같이 제조된 본 발명의 새로운 조성물에 대해, 급성독성 시험과 고지방 식이(High lipid diet) 혼합사료에 의한 고지혈증을 유발시켜 효력시험을 실시하였다.For the novel composition of the present invention prepared as described above, an acute toxicity test and an efficacy test were conducted by inducing hyperlipidemia by a high fat diet mixed feed.

본 발명의 새로운 조성물에 대한 효력 시험 결과, 본 발명의 새로운 조성물이 고지혈증에 월등한 효과를 나타내었다.As a result of the efficacy test on the new composition of the present invention, the new composition of the present invention showed a superior effect on hyperlipidemia.

본 발명의 건강 기능 식품은 통상 성인 기준 1 일 3 회, 1 회 2 캅셀(1 캅셀 450 mg기준)씩 물로 복용하는 것이 추천된다. 물론 복용자의 상태에 따라 적의증감이 가능하다.It is recommended that the health functional food of the present invention be taken with water, 2 capsules (based on 450 mg of 1 capsule) at a time, 3 times a day for adults. Of course, it is possible to increase or decrease the enemy according to the condition of the user.

이하 실시예 및 실험예를 통하여 본 발명을 더욱 상세히 설명하나 본 발명이 이에 국한되는 것은 아니다.The present invention will be described in more detail through the following examples and experimental examples, but the present invention is not limited thereto.

실시예 1 : 새로운 조성물의 처방.Example 1: Prescription of a new composition.

운지버섯(자실체)추출물분말 45.0 %, 단삼추출물분말 20.0 %, 갈근추출물분말 15.0 %, 천궁추출물분말 5.0 %, 홍화씨추출물분말 5.0 %, 산사자추출물분말 10.0 %,Unji mushroom (fruiting body) extract powder 45.0%, Danseng extract powder 20.0%, radish root extract powder 15.0%, cnidium extract powder 5.0%, safflower seed extract powder 5.0%, hawthorn extract powder 10.0%,

실시예 2 : 새로운 조성의 추출물분말 제조방법.Example 2: Manufacturing method of extract powder with new composition.

① 운지버섯추출물분말의 제조.① Manufacture of Unji mushroom extract powder.

운지버섯(자실체)을 일정한 크기로 절단하고 810 g을 정확하게 칭량하여 오토 클레이브 추출기에 넣고, 10 배량의정제수를 가하여, 121 도씨에서 2 시간동안 추출한 다음, 50 μm의 필터로 여과하여 1/10 량으로 농축한 후 3 배량의 에탄올을 가하고 12 시간동안 방치한다. 침전물이 형성된 후 여과하여 침전물을 수거한 다음 비스킹 튜브(Visking tube)를 사용하여 흐르는 물에 48 시간동안투석하고, 동결 건조 처리하여 운지버섯추출물분말 202.5 g을제조한다.Cut the finger mushrooms (fruiting body) into a certain size, accurately weigh 810 g, put it in an autoclave extractor, add 10 times the amount of purified water, extract at 121 degrees Celsius for 2 hours, filter with a 50 μm filter, and reduce the amount by 1/10 After concentrating to , 3 times the amount of ethanol was added and left for 12 hours. After the precipitate is formed, the precipitate is collected by filtration, then dialyzed in running water for 48 hours using a Visking tube, and lyophilized to prepare 202.5 g of mushroom extract powder.

② 단삼추출물분말의 제조.② Manufacture of Danshen extract powder.

단삼 322.65 g을 정밀히 달아 오토 클레이브 추출기에 넣고 10 배량의 정제수를 가하여 121 ℃에서 2 시간추출하고, 50 μm의 필터로 여과하고, 동결 건조 처리하여 단삼추출물분말 90 g을 제조한다.322.65 g of Danshen was precisely weighed, put in an autoclave extractor, added with 10 times the amount of purified water, extracted at 121 ° C for 2 hours, filtered through a 50 μm filter, and lyophilized to prepare 90 g of Danshen extract powder.

③ 갈근추출물분말의 제조.③ Manufacture of algae root extract powder.

갈근 211.95 g을 정밀히 달아 오토 클레이브 추출기에 넣고 10 배량의 정제수를 가하여 121 ℃에서 2 시간추출하고, 50 μm의 필터로 여과하고, 동결 건조 처리하여 갈근추출물분말 22.5 g을 제조한다.211.95 g of brown root was precisely weighed, put in an autoclave extractor, extracted with 10 times the amount of purified water at 121 ° C for 2 hours, filtered through a 50 μm filter, and lyophilized to prepare 22.5 g of brown root extract powder.

④ 천궁추출물분말의 제조.④ Manufacture of cnidium extract powder.

천궁 63.45 g을 정밀히 달아 오토 클레이브 추출기에 넣고 10 배량의 정제수를 가하여 121 ℃ 2 시간추출하고, 50μm의 필터로 여과하고, 동결 건조 처리하여 천궁추출물분말 22.5 g을 제조한다.Weigh 63.45 g of cnidium precisely, put it in an autoclave extractor, add 10 times the amount of purified water, extract at 121 ° C for 2 hours, filter with a 50 μm filter, and freeze-dry to prepare 22.5 g of cnidium extract powder.

⑤ 홍화씨추출물분말의 제조.⑤ Manufacture of safflower seed extract powder.

홍화씨 73.8 g을 정밀히 달아 오토 클레이브 추출기에 넣고 10 배량의 정제수를 가하여 121 ℃에서 2 시간추출하고, 50 μm의 필터로 여과하고, 동결 건조 처리하여 홍화씨추출물분말 22.5 g을 제조한다.Precisely weigh 73.8 g of safflower seeds, put them in an autoclave extractor, add 10 times the amount of purified water, extract at 121 ° C for 2 hours, filter through a 50 μm filter, and freeze-dry to prepare 22.5 g of safflower seed extract powder.

⑥ 산사자추출물분말의 제조.⑥ Manufacture of hawthorn extract powder.

산사자 127.35 g을 정밀히 달아 오토 클레이브 추출기에 넣고 10 배량의 정제수를 가하여 121 ℃에서 2 시간추출하고, 50 μm의 필터로 여과하고, 동결 건조 처리하여 산사자추출물분말 45.0 g을 제조한다.127.35 g of hawthorn was precisely weighed, put in an autoclave extractor, and 10 times the amount of purified water was added, extracted at 121 ° C for 2 hours, filtered through a 50 μm filter, and lyophilized to prepare 45.0 g of hawthorn extract powder.

실시예 3 : 새로운 조성물의 캅셀제 제조방법.Example 3: Manufacturing method of capsules of new composition.

실시예 2에서 얻은 운지버섯(자실체)추출물분말 202.5 g, 단삼추출물분말 90.0 g, 갈근추출물분말 67.5 g, 천궁추출물분말 22.5 g, 홍화씨추출물분말 22.5 g, 산사자추출물분말 45.0 g을 정밀히 달아 연합기에 넣고, 정제수 20 g을 가하고 잘 혼합 연합한 다음, 과립기를 사용하여 과립을 만든 다음, 60 도씨 이하로 건조하여 과립을 만든 다음,경질캅셀 충진기를 사용하여 경질캅셀에 1 캅셀당 450 mg씩 충진하여 경질캅셀을 제조한다. 실시예 4 : 새로운 조성물의 환제 제조방법.실시예 2에서 얻은 운지버섯(자실체)추출물분말 202.5 g, 단삼추출물분말 90.0 g, 갈근추출물분말 67.5 g, 천궁추출물분말 22.5 g, 홍화씨추출물분말 22.5 g, 산사자추출물분말 45.0 g을 정밀히 달아 연합기에 넣고 정제수 40 g을가하고 잘 혼합 연합한 다음, 환제 제조기를 사용하여 환제를 제조한 후, 60 도씨 이하로 건조하여 환제를 만든다. 1환의 중량은 150 mg으로 제조한다.202.5 g of Unji mushroom (fruiting body) extract powder obtained in Example 2, 90.0 g of Danseng extract powder, 67.5 g of radish root extract powder, 22.5 g of cnidium extract powder, 22.5 g of safflower seed extract powder, and 45.0 g of hawthorn extract powder were precisely weighed and put into a blender. , Add 20 g of purified water, mix well, make granules using a granulator, make granules by drying below 60 degrees Celsius, and then use a hard capsule filling machine to fill hard capsules at 450 mg per capsule. Prepare hard capsules. Example 4: Method for preparing pills of a new composition. 202.5 g of mushroom (fruiting body) extract powder obtained in Example 2, 90.0 g of danseng extract powder, 67.5 g of radish root extract powder, 22.5 g of cnidium extract powder, 22.5 g of safflower seed extract powder, Precisely weigh 45.0 g of hawthorn extract powder, put it in a blender, add 40 g of purified water, mix well, prepare a pill using a pill maker, and then dry it below 60 degrees Celsius to make a pill. The weight of one ring is prepared as 150 mg.

실시예 5 : 새로운 조성물의 액제 제조방법.Example 5: Method for preparing a liquid formulation of a new composition.

실시예 2에서 얻은 운지버섯(자실체)추출물분말 202.5 g, 단삼추출물분말 90.0 g, 갈근추출물분말 67.5 g, 천궁추출물분말 22.5 g, 홍화씨추출물분말 22.5 g, 산사자추출물분말 45.0 g을 정밀히 달아 혼합탱크에 넣고 정제수6000 ml과 스테비오사이드 5 g을 가하여 잘 용해 혼합한 다음, 정제수를 가하여 전체 용량을 7000 ml로 조정한 다음, 충분히 교반하여 균질화 시키고 50 μm의 필터로 여과하고, 140 ml용량의 폴리에틸렌용기에 충전 제조한다.202.5 g of Unji mushroom (fruiting body) extract powder obtained in Example 2, 90.0 g of Danseng extract powder, 67.5 g of radish root extract powder, 22.5 g of cnidium extract powder, 22.5 g of safflower seed extract powder, and 45.0 g of hawthorn extract powder were precisely weighed in a mixing tank. 6000 ml of purified water and 5 g of stevioside were added, dissolved and mixed well, then added with purified water to adjust the total volume to 7000 ml, sufficiently stirred to homogenize, filtered through a 50 μm filter, and placed in a polyethylene container with a capacity of 140 ml. make a filling

실시예 6 : 새로운 조성물의 과립제 제조방법.Example 6: Manufacturing method of granules of new composition.

실시예 2에서 얻은 운지버섯(자실체)추출물분말 202.5 g, 단삼추출물분말 90.0 g, 갈근추출물분말 67.5 g, 천궁추출물분말 22.5 g, 홍화씨추출물분말 22.5 g, 산사자추출물분말 45.0 g을 정밀히 달아 연합기에 넣고, 정제수 40 g을 가하고 잘 혼합 연합한 다음 과립기를 사용하여 과립을 만든 다음, 60 도씨 이하로 건조하여 과립을 만든 다음,60 도씨 이하로 건조하여 과립 450 g을 제조한다.202.5 g of Unji mushroom (fruiting body) extract powder obtained in Example 2, 90.0 g of Danseng extract powder, 67.5 g of radish root extract powder, 22.5 g of cnidium extract powder, 22.5 g of safflower seed extract powder, and 45.0 g of hawthorn extract powder were precisely weighed and put into a blender. , Add 40 g of purified water, mix well, make granules using a granulator, dry below 60 degrees Celsius to make granules, and then dry below 60 degrees Celsius to prepare 450 g of granules.

실시예 7 : 새로운 조성물의 정제 제조방법.Example 7: Method for manufacturing tablets of the new composition.

실시예 2에서 얻은 운지버섯(자실체)추출물분말 202.5 g, 단삼추출물분말 90.0 g, 갈근추출물분말 67.5 g, 천궁추출물분말 22.5 g, 홍화씨추출물분말 22.5 g, 산사자추출물분말 45.0 g을 정밀히 달아 연합기에 넣고, 옥수수전분20 g, 유당 30 g, 정제수 40 g을 가하고 잘 혼합 연합한 다음 과립기를 사용하여 과립을 만든 다음, 60 도씨 이하로건조하여 과립을 만든 다음, 60 도씨 이하로 건조하여 과립을 만든 다음, 여기에 스테아린산 마그네슘 4 g을 가하고직접 타정하여 1정의 중량이 500 mg인 정제를 제조한다.202.5 g of Unji mushroom (fruiting body) extract powder obtained in Example 2, 90.0 g of Danseng extract powder, 67.5 g of radish root extract powder, 22.5 g of cnidium extract powder, 22.5 g of safflower seed extract powder, and 45.0 g of hawthorn extract powder were precisely weighed and put into a blender. , Add 20 g of corn starch, 30 g of lactose, and 40 g of purified water, mix well, make granules using a granulator, dry below 60 degrees Celsius to make granules, and then dry below 60 degrees Celsius to make granules. After preparation, 4 g of magnesium stearate is added thereto and compressed into tablets directly to prepare tablets having a weight of 500 mg per tablet.

실험예 1 : 추출 조건에 따른 운지버섯추출물분말 및 운지버섯(자실체)의 활성성분인 운지버섯다당체 수율시험.Experimental Example 1: Yield test of mushroom extract powder and mushroom polysaccharide, which is an active ingredient of mushroom mushroom (fruiting body), according to extraction conditions.

1) 운지버섯추출물분말의 제조방법1) Manufacturing method of mushroom extract powder

① 오토 클레이브 추출법① Autoclave extraction method

운지버섯(자실체)을 일정한 크기로 절단하고, 정확하게 칭량하여 오토 클레이브 추출기에 넣고, 10 배량의 정제수를 가하여, 121 도씨에서 1, 2, 3 시간동안 추출한 다음, 50 μm의 필터로 여과하여 1/10 량으로 농축한 후 3 배량의에탄올을 가하고 12 시간 동안 방치한다. 침전물이 형성된 후 여과하여 침전물을 수거한 다음 비스킹 튜브(Viskingtube)를 사용하여 흐르는 물에 48 시간동안 투석하고 동결 건조 처리하여 각각의 운지버섯추출물분말을 제조한다.Cut the finger mushrooms (fruiting bodies) into a certain size, accurately weigh them, put them in an autoclave extractor, add 10 times the amount of purified water, extract them at 121 degrees Celsius for 1, 2, and 3 hours, filter them with a 50 μm filter, and After concentrating to 10%, 3 times the amount of ethanol was added and allowed to stand for 12 hours. After the precipitate is formed, the precipitate is collected by filtration, then dialyzed in running water for 48 hours using a Visking tube, and freeze-dried to prepare each fingerling mushroom extract powder.

② 열수 추출법② Hot water extraction method

운지버섯(자실체)을 일정한 크기로 절단하고, 정확하게 칭량하여 환류추출기에 넣고, 10 배량의 정제수를 가하고,100 도씨에서 3, 6, 12 시간동안 추출한 다음, 50 μm의 필터로 여과하여 1/10 량으로 농축한 후 3 배량의 에탄올을가하고 12 시간 동안 방치한다. 침전물이 형성된 후 여과하여 침전물을 수거한 다음 비스킹 튜브(Visking tube)를사용하여 흐르는 물에 48 시간동안 투석하고 동결 건조 처리하여 각각의 운지버섯추출물분말을 제조한다.Cut the Unji mushroom (fruiting body) into a certain size, accurately weigh it, put it in a reflux extractor, add 10 times the amount of purified water, extract it at 100 degrees Celsius for 3, 6, and 12 hours, filter it with a 50 μm filter to obtain 1/10 After concentrating to the same amount, 3 times the amount of ethanol is added and left for 12 hours. After the precipitate is formed, the precipitate is collected by filtration, then dialyzed in running water for 48 hours using a Visking tube, and freeze-dried to prepare each mushroom extract powder.

③ 수율 계산③ Yield calculation

운지버섯추출물분말 수율(w/w)%= 운지버섯추출물분말의 수득량 ÷운지버섯의 사용량 ×100Mushroom extract powder yield (w/w)% = yield of mushroom extract powder ÷ amount of mushroom extract × 100

2) 운지버섯다당체의 함량2) Content of mushroom polysaccharide

① 실험방법① Experiment method

운지버섯추출물분말에 안트론(anthrone)시약과 반응시켜 나타나는 발색도를 U.V. spectrophotometer를 사용하여 파장 625 nm에서 흡광도를 측정하였으며, 포도당(glucose)으로 작성한 검량곡선으로부터 운지버섯다당체의 함량을 계산하였다.U.V. Absorbance was measured at a wavelength of 625 nm using a spectrophotometer, and the content of mushroom polysaccharide was calculated from a calibration curve prepared with glucose.

② 수율 계산② Yield calculation

운지버섯다당체 수율(w/w)%=운지버섯다당체의 함량 ÷운지버섯의 사용량 ×100Mushroom polysaccharide yield (w/w)% = Content of Mushroom polysaccharide ÷ Amount of Mushroom Mushroom × 100

3) 실험결과(표1 참조)3) Experimental results (see Table 1)

운지버섯추출물분말의 수율은 열수추출법(100 ℃)에서 3 시간은 13.42 %, 6 시간은 16.54 %, 12 시간은 18.52 %의 결과를 얻었고, 오토 클레이브법(121 ℃, 1 기압)에서는 1 시간은 15.83 %, 2 시간은 25.0 %, 3 시간은 24.8 %의 결과를 얻었다.The yield of the mushroom extract powder was 13.42% for 3 hours, 16.54% for 6 hours, and 18.52% for 12 hours in the hot water extraction method (100 ℃), and in the autoclave method (121 ℃, 1 atm), 1 hour 15.83%, 2 hours yielded 25.0%, and 3 hours yielded 24.8% results.

같은 추출시간대인 3 시간에서는 열수추출법(100 ℃)에서 13.42 % 이고, 오토 클레이브법(121 ℃, 1 기압)에서는24.8 %의 결과를 얻었다.In the same extraction time period of 3 hours, the hot water extraction method (100 ℃) was 13.42%, and the autoclave method (121 ℃, 1 atm) was 24.8%.

따라서 같은 추출시간대에서 오토 클레이브법에 따른 운지버섯추출물분말의 수율이 약 1.8배 향상되었다.또한 운지버섯다당체의 수율은 열수추출법(100 ℃)에서 3 시간은 8.69 %, 6 시간은 10.70 %, 12 시간은 11.76 %의 결과를 얻었고, 오토 클레이브법(121 ℃, 1 기압)에서는 1 시간은 10.34 %, 2 시간은 16.33 %, 3 시간은16.02 %의 결과를 얻었다.Therefore, in the same extraction time period, the yield of the mushroom extract powder according to the autoclave method was improved by about 1.8 times. In addition, the yield of mushroom polysaccharide was 8.69% for 3 hours, 10.70% for 6 hours, and 12 The time obtained a result of 11.76%, and in the autoclave method (121 ℃, 1 atm), 10.34% for 1 hour, 16.33% for 2 hours, and 16.02% for 3 hours.

같은 추출시간대인 3 시간에서는 열수추출법(100 ℃)에서 8.69 %이고, 오토 클레이브법(121 ℃, 1 기압)에서는16.02 %의 결과를 얻었다.In the same extraction time period of 3 hours, the hot water extraction method (100 ℃) was 8.69%, and the autoclave method (121 ℃, 1 atmospheric pressure) obtained a result of 16.02%.

따라서, 같은 추출시간대에서 오토 클레이브법에 따른 운지버섯다당체의 수율이 약 1.8배 향상되었다.열수추출법(100 ℃)에서는 운지버섯추출물분말과 운지버섯다당체의 수율은 추출시간이 길수록 수율이 증가하는경향을 보이고 있으나, 오토 클레이브법(121 ℃, 1 기압)에서는 2 시간에서 25.0 %이고, 3 시간에서는 24.8 %으로추출시간이 증가함에 따라 운지버섯추출물분말의 수율이 점차적으로 감소하고 있는 결과로 볼 때, 2 시간 추출이더 효과적인 것으로 나타났고, 2 시간이상 추출은 운지버섯추출물분말의 수율에 큰 영향을 미치지 않는 것으로 나타났다.Therefore, in the same extraction time period, the yield of the mushroom polysaccharide produced by the autoclave method was improved by about 1.8 times. However, in the autoclave method (121 ℃, 1 atm), it is 25.0% at 2 hours and 24.8% at 3 hours. As a result, the yield of mushroom extract powder gradually decreases as the extraction time increases. , extraction for 2 hours was found to be more effective, and extraction for more than 2 hours did not significantly affect the yield of mushroom extract powder.

운지버섯다당체의 수율에 있어서도 큰 영향을 미치지 않는 것으로 나타났다.It was also found that there was no significant effect on the yield of the mushroom polysaccharide.

따라서, 이들의 실험결과를 비교하여 본다면, 열수추출법(100 ℃)으로 장시간 추출하는 것보다는, 오토 클레이브법(121 ℃, 1 기압)으로 최적시간인 2 시간동안 단시간에 추출하는 것이 경제적이며, 효율적이다.Therefore, comparing these experimental results, it is economical and efficient to extract in a short time for 2 hours, which is the optimal time, by the autoclave method (121 ° C, 1 atm) rather than extracting for a long time by the hot water extraction method (100 ° C). to be.

실험예 4 : 새로운 조성물의 효력시험.Experimental Example 4: Efficacy test of the new composition.

1) 실험동물1) Experimental animals

Sprague-Dawley(SD)계 흰쥐(체중 120∼160 g)를 구입하여, 실험실에서 약 10 일간 순환적응 시킨후 건강한 동물을 선택하여 온도 23±3 ℃, 상대습도 50±10 %, 배기 10∼12 회, 형광등 명암 12 hr cycle, 조도 150∼160 Lux의 환경에서 사육하였다.시험기간 동안 고형사료 및 물을 충분히 공급하였다.Sprague-Dawley (SD) rats (weight 120∼160 g) were purchased, and after circulatory adaptation in the laboratory for about 10 days, healthy animals were selected and the temperature was 23±3 ℃, the relative humidity was 50±10%, and the exhaust was 10∼12 They were reared in an environment of 150-160 Lux, 12 hr cycle of light and shade under fluorescent lamps. Solid feed and water were sufficiently supplied during the test period.

2) 실험검체의 조제2) Preparation of test samples

실시예 3의 캅셀제 혼합분말을 실험 투여용량에 따라 정제수에 카르복시메칠셀룰로오스나트륨을 가하고, 용시 현탁하여 실험검체로 사용하였다.Sodium carboxymethylcellulose was added to purified water according to the dose of the capsule formulation of Example 3, and suspended at the time of use, and used as an experimental sample.

3) 고지방 식이 혼합사료3) High-fat diet mixed feed

고지방 식이 혼합사료는 버터(butter) : 콜레스테롤(cholesterol) : 바일쥬스 (bile juice) : 계란노른자(egg yolk) :분말사료를 3 : 0.5 : 0.2 : 3 : 9의 비율로 혼합, 제조하였다.The high-fat diet mixture was prepared by mixing butter: cholesterol: bile juice: egg yolk: powder feed at a ratio of 3: 0.5: 0.2: 3: 9.

4) 실험방법4) Experiment method

① 고지방 식이(High lipid diet) 혼합사료에 의한 고지혈증의 유발① Induction of hyperlipidemia by high-fat diet mixed feed

Sprague-Dawley(SD)계 흰쥐 암컷에 고지방식이(High lipid diet) 혼합사료를 15 일간 투여하여 고지혈증을 유발시킨후, 평균 250 g의 흰쥐를 선별하여 실험에 사용하였다.High lipid diet mixed feed was administered to female Sprague-Dawley (SD) rats for 15 days to induce hyperlipidemia, and rats with an average weight of 250 g were selected and used in the experiment.

② 시료의 투여② Sample administration

흰쥐 6마리를 1군으로 하여, 정상군에는 분말사료를 투여하였고, 대조군은 고지방식이(High lipid diet) 혼합사료를15 일간 투여하여 고지혈증을 유발시킨 흰쥐를, 실험군은 고지혈증을 유발시킨 흰쥐에 운지버섯추출물분말(실시예2의 1)참조)과 새로운 조성물(실시예 3참조)을 각군당 50 mg/kg, 100 mg/kg, 300 mg/kg을 14 일간 1 일 1 회 경구 투여하였다.Six rats were grouped into one group, the normal group was fed powdered feed, the control group was rats induced with hyperlipidemia by administering a high-fat diet mixed feed for 15 days, and the experimental group was rats with hyperlipidemia. The mushroom extract powder (see Example 2, 1)) and the new composition (see Example 3) were orally administered at 50 mg/kg, 100 mg/kg, and 300 mg/kg per group once a day for 14 days.

③ 혈액 채취 및 혈청 분리③ Blood collection and serum separation

흰쥐를 고지방식이(High lipid diet) 혼합사료로 사육하고 실험검체를 최종투여한 1 일후에 흰쥐를 에텔(ether) 마취하에서 경동맥을 절단하여 채혈하고 실온에서 20 분간 방치한 다음, 3,000 r.p.m에서 15 분간 원심 분리하여 혈청을 분리하였다.Rats were reared on a high-fat diet mixed feed, and 1 day after the final administration of the test specimen, the carotid artery was cut and blood was collected from the rats under ether anesthesia. Serum was separated by centrifugation for 10 minutes.

④ 혈청중의 트랜스아미나제(transaminase) 활성도 측정④ Measurement of transaminase activity in serum

혈청중의 GOT, GPT 활성도의 측정은 라이트만-프랑클(Reitman- Frankel)법에 준하여 U.V. spectrophotometer를 사용하여 파장 505 nm에서 측정하였다.The measurement of GOT and GPT activities in serum was carried out according to the Reitman-Frankel method by U.V. It was measured at a wavelength of 505 nm using a spectrophotometer.

⑤ 혈청중 총 콜레스테롤(Total Cholesterol) 함량측정 혈청중 총 콜레스테롤(Total Cholesterol) 함량측정은 Rapid Blood Analyzer <RaBA>와 콜레스테롤(Cholesterol) 측정용 kit 시약을 사용하여 측정하였다.⑤ Measurement of Total Cholesterol Content in Serum The total cholesterol content in serum was measured using a Rapid Blood Analyzer <RaBA> and cholesterol measuring kit reagents.

⑥ 혈청중 트리글리세라이드(Triglyceride) 함량측정⑥ Measurement of triglyceride content in serum

혈청중트리글리세라이드(Triglyceride) 함량측정은 Spectrophotometer와 Triglyceride 측정용 kit 시약을 사용하여 파장 500 nm에서 측정하였다.Triglyceride content in serum was measured at a wavelength of 500 nm using a spectrophotometer and a kit reagent for measuring triglyceride.

⑦ 혈청중의 고밀도 지단백 콜레스테롤(HDL-Cholesterol) 함량측정⑦ Measurement of HDL-Cholesterol content in serum

혈청중의 고밀도 지단백 콜레스테롤(HDL-Cholesterol) 함량측정은 Enzymatic Colorimetric 법에 준하여 U.V.spectrophotometer를 사용하여 파장 505 nm에서 측정하였다.High-density lipoprotein cholesterol (HDL-Cholesterol) content in serum was measured at a wavelength of 505 nm using a U.V.spectrophotometer according to the Enzymatic Colorimetric method.

5) 실험결과 및 고찰.5) Experiment results and consideration.

고지방식이로 15 일간 사육하여 고지혈증을 유발시킨 쥐에 대한 새로운 조성물 및 운지버섯추추물분말 단독 투여에의한 실험 결과는 다음과 같다.The results of the experiment by administering the new composition and the mushroom extract powder alone to rats raised on a high-fat diet for 15 days to induce hyperlipidemia are as follows.

① 고지방 식이(High lipid diet) 혼합사료 단독 투여가 고지혈에 미치는 영향.① Effect of high lipid diet mixed feed alone on hyperlipidemia.

정상군의 혈청중 총 콜레스테롤(Ttal Cholesterol)함량은 47.9±6.8 mg/dl이고, 고지방 식이(High lipid diet) 혼합사료 단독 투여하여 고지혈증을 유발시킨 대조군의 총 콜레스테롤(Total Cholesterol)함량은 141.5±13.4 mg/dl로, 정상군에 비하여 총 콜레스테롤(Total Cholesterol)함량이 현저하게 증가하여 고지혈을 유발하기에 충분하였다.The total cholesterol content in the serum of the normal group was 47.9±6.8 mg/dl, and the total cholesterol content of the control group induced hyperlipidemia by administering the high-fat diet mixed feed alone was 141.5±13.4 At mg/dl, the total cholesterol (Total Cholesterol) content significantly increased compared to the normal group, which was sufficient to induce hyperlipidemia.

한편, 혈청중 트리글리세라이드(Triglyceride)함량은 정상군이 64.5±2.9 mg/dl, 대조군이 201.7±18.3 mg/dl 이고, 또한 고밀도 지단백 콜레스테롤(HDL-Cholesterol)함량은 정상군이 13.9±1.8 mg/dl, 대조군이 25.3±2.1mg/dl 로 역시 유의성있는 증가를 나타내었다.On the other hand, triglyceride content in serum was 64.5±2.9 mg/dl in the normal group and 201.7±18.3 mg/dl in the control group, and HDL-Cholesterol content was 13.9±1.8 mg/dl in the normal group. dl, the control group also showed a significant increase to 25.3±2.1mg/dl.

② 고지혈증 유발 흰쥐에 미치는 운지버섯추출물분말 단독투여의 영향.② Effects of single administration of gungji mushroom extract powder on hyperlipidemia-induced rats.

고지방 식이(Hight lipid diet)혼합사료를 단독 투여한 대조군에 비하여 일반적으로 운지버섯추출물분말을 투여한시험군은 용량의존적으로 GOT, GPT 치의 강하를 나타내었다.운지버섯추출물분말 50 mg/kg, 100 mg/kg과 300 mg/kg을 각각 1일 1회 투여하고 시험한 결과, 이들 시험군들의GOT치는 각각 175.8±13.4, 167.3±12.1와 134.5±11.9 으로, 대조군의 GOT 치 387.4±21.6 에 비하여 용량 의존적으로 유의성 있는 GOT치의 강하를 보였다.이들 시험군들의 GPT 치는 각각 88.7±3.5, 86.4±4.2 와 80.6±5.8 으로, 대조군의 GPT 치 249.3±25.4에 비하여 용량 의존적으로 유의성있는 GPT 치의 강하를 보였다.이들 시험군들의 혈청중 총 콜레스테롤(Total Cholesterol)함량은 각각 81.2±3.4 mg/dl, 78.5±4.6 mg/dl와72.4±3.9 mg/dl으로, 운지버섯추출물분말 50 mg/kg, 100 mg/kg과 300 mg/kg을 투여한 군에서는 고지방 식이(High lipid diet)혼합사료를 단독 투여한 대조군의 총 콜레스테롤(Total Cholesterol)함량인 141.5±13.4 mg/dl에비하여 용량 의존적으로 유의성있는 결과를 보였다.Compared to the control group administered with the high-fat diet mixed feed alone, the test group administered with mushroom extract powder generally showed a decrease in GOT and GPT values in a dose-dependent manner. Mushroom extract powder 50 mg/kg, 100 As a result of the test after administering mg/kg and 300 mg/kg once a day, respectively, the GOT values of these test groups were 175.8±13.4, 167.3±12.1, and 134.5±11.9, respectively, compared to the GOT value of 387.4±21.6 in the control group. The GPT values of these test groups were 88.7±3.5, 86.4±4.2, and 80.6±5.8, respectively, showing a significant drop in GPT value in a dose-dependent manner compared to the GPT value of 249.3±25.4 in the control group. The total cholesterol (Total Cholesterol) content in the serum of these test groups was 81.2±3.4 mg/dl, 78.5±4.6 mg/dl, and 72.4±3.9 mg/dl, respectively. In the group administered with and 300 mg/kg, a significant result was shown in a dose-dependent manner compared to the total cholesterol content of 141.5±13.4 mg/dl in the control group administered with the high lipid diet mixed feed alone.

한편, 이들 시험군들의 혈청중 트리글리세라이드(Triglyceride)함량은 각각 56.2±5.9 mg/dl, 54.7±4.1 mg/dl와49.8±5.6 mg/dl 로 고지방 식이(High lipid diet)혼합사료를 단독 투여한 대조군의 혈청중 트리글리세라이드(Triglyceride)함량인 201.7±18.3 mg/dl 에 비하여 모두 유의성 있는 결과를 보였으며, 정상군의 혈청중 트리글리세라이드(Triglyceride)함량인 64.5±2.9 mg/dl 보다도 오히려 저하된 결과를 나타내었다.또한, 고밀도 지단백 콜레스테롤(HDL-Cholesterol)함량은 대조군이 25.3±2.1 mg/dl으로, 이들 시험군은 각각11.4±1.9 mg/dl, 12.7±1.2 mg/dl와 14.5±1.5 mg/dl로 대조군과 비교할때 유의성 있는 상승 억제 효과를 나타내었다.On the other hand, triglyceride content in the serum of these test groups was 56.2±5.9 mg/dl, 54.7±4.1 mg/dl, and 49.8±5.6 mg/dl, respectively. Compared to the serum triglyceride content of the control group, 201.7 ± 18.3 mg / dl, all showed significant results, and the result was rather lower than the triglyceride content of the normal group, 64.5 ± 2.9 mg / dl In addition, the high-density lipoprotein cholesterol (HDL-Cholesterol) content was 25.3±2.1 mg/dl in the control group, and 11.4±1.9 mg/dl, 12.7±1.2 mg/dl and 14.5±1.5 mg/dl in these test groups, respectively. dl showed a significant synergistic inhibitory effect when compared to the control group.

③ 고지혈증 유발 흰쥐에 미치는 본 발명에 따른 새로운 조성물 투여의 영향.③ Effect of administration of the new composition according to the present invention on hyperlipidemia-induced rats.

가) 혈청중의 트랜스아미나제(transaminase) 활성도ⅰ) GOT, GPT활성도에 미치는 효과흰쥐를 고지방식이(High lipid diet)혼합사료로 사육하여 고지혈증을 유발시키고 새로운 조성물을 투여한 후에 혈중GOT치에 미치는 효과를 보면, 정상군은 119.5±13.2 이고, 고지혈증을 유발시킨 대조군은 387.4±21.6 로 상승하였다. 정상군에 비하여 혈중 GOT치가 현저하게 증가하여 고지혈증을 유발하기에 충분하였다.A) Transaminase activity in serum ⅰ) Effect on GOT and GPT activity Looking at the effect, the normal group was 119.5±13.2, and the hyperlipidemia-induced control group rose to 387.4±21.6. Compared to the normal group, the GOT level in the blood significantly increased, which was sufficient to induce hyperlipidemia.

ii) 혈청중 총 콜레스테롤(Total Cholesterol), 혈청중 트리글리세라이드 (Triglyceride), 고밀도 지단백 콜레스테롤(HDL-Cholesterol)함량.ii) Total Cholesterol, Triglyceride, and HDL-Cholesterol in Serum.

고지방 식이(High lipid diet)혼합 사료만을 투여한 대조군에 비하여 일반적으로 새로운 조성물을 투여한 시험군은용량 의존적으로 현저한 고지혈증 억제를 나타내었다.Compared to the control group administered with only the high-fat diet mixed feed, in general, the test group administered with the new composition exhibited significant suppression of hyperlipidemia in a dose-dependent manner.

본 발명에 따른 새로운 조성물 50 mg/kg, 100 mg/kg과 300 mg/kg을 각각 1 일 1 회 투여하고 시험한 결과,이들 시험군들의 혈청중 총 콜레스테롤(Total Cholesterol)함량은 각각 75.7±6.3 mg/dl, 71.4±5.8 mg/dl와52.9±3.5 mg/dl으로 고지방 식이(High lipid diet)혼합 사료만을 단독투여한 대조군의 총 콜레스테롤(TotalCholesterol)함량인 141.5±13.4 mg/dl에 비하여 용량 의존적으로 유의성있는 결과를 보였다.한편, 이들 시험군들의 혈청중 트리글리세라이드(triglyceride)함량은 각각 53.5 ±4.2 mg/dl, 49.3±3.5 mg/dl와48.9±5.8 mg/dl로 고지방 식이(High lipid diet)혼합 사료만을 독 투여한 대조군의 트리글리세라이드(triglyceride)함량인 201.7±18.3 mg/dl에 비하여 모두 유의성있는 결과 보였으며, 본 발명에 따른 새로운조성물(실시예3)100 mg/kg과 300 mg/kg 투여에 의한 트리글리세라이드(trigly-ceride) 함량은 49.3±3.5 mg/dl와48.9±5.8 mg/dl은 정상군의 트리글리세라이드(triglyceride)함량인 64.5±2.9 mg/dl 에 비하여 현저한 저하작용을 보였다.50 mg/kg, 100 mg/kg, and 300 mg/kg of the new composition according to the present invention were administered and tested once a day, respectively. As a result, the total cholesterol content in the serum of these test groups was 75.7 ± 6.3, respectively. mg/dl, 71.4±5.8 mg/dl and 52.9±3.5 mg/dl, dose-dependent compared to the total cholesterol content of 141.5±13.4 mg/dl in the control group administered only with the high-fat diet mixed feed alone Meanwhile, the serum triglyceride content of these test groups was 53.5 ± 4.2 mg/dl, 49.3 ± 3.5 mg/dl, and 48.9 ± 5.8 mg/dl, respectively. ) Compared to the triglyceride content of 201.7 ± 18.3 mg / dl of the control group in which only the mixed feed was poisoned, all significant results were shown, and the new composition according to the present invention (Example 3) 100 mg / kg and 300 mg / kg The triglyceride content by kg administration was 49.3 ± 3.5 mg/dl and 48.9 ± 5.8 mg/dl, which showed a significant decrease compared to the normal group's triglyceride content of 64.5 ± 2.9 mg/dl. .

나아가, 혈청중 고밀도 지단백 콜레스테롤(HDL-cholesterol)함량에 미치는 영향을 살펴보면, 고지방 식이(Highlipid diet)혼합 사료만을 단독 투여한 대조군에 비하여,Furthermore, looking at the effect on the content of high-density lipoprotein cholesterol (HDL-cholesterol) in serum, compared to the control group administered only the high-fat diet mixed feed alone,

본 발명의 새로운 조성물 50 mg/kg, 100 mg/kg과 300 mg/kg의 투여에 의한 고밀도 지단백 콜레스테롤(HDLcholesterol)함량은 11.6±1.7 mg/dl, 12.8±1.3 mg/dl와 19.3±2.6 mg/dl로써, 고지방 식이(High lipid diet) 혼합사료만을 투여한 대조군의 고밀도 지단백 콜레스테롤(HDL-cholesterol)함량은 25.3±2.1 mg/dl에 비하여 현저한고밀도 지단백 콜레스테롤(HDL-cholesterol)함량 저하 작용을 보였다.The high-density lipoprotein cholesterol (HDLcholesterol) content by administration of 50 mg/kg, 100 mg/kg and 300 mg/kg of the new composition of the present invention was 11.6±1.7 mg/dl, 12.8±1.3 mg/dl and 19.3±2.6 mg/dl. As dl, the high-density lipoprotein-cholesterol (HDL-cholesterol) content of the control group administered only with the high-fat diet mixed feed was 25.3±2.1 mg/dl.

Claims (1)

1) 운지버섯(자실체)을 110~130 ℃에서 2-3 시간동안 물, 에탄올 또는 이들의 혼합용액 중에서 선택한 1종의 용매로 오토 클레이브 추출기에서 추출하고, 여과 농축한 다음 동결 또는 분무건조시킨 운지버섯추출물분말 35.0∼55.0중량 %와 2) 단삼, 갈근, 천궁, 홍화씨 및 산사자를 110~130 ℃에서 2-3 시간동안 각각 별도로 물, 에탄올 또는 이들의 혼합용액 중에서 선택한 1종의 용매로 오토 클레이브 추출기에서 추출하고, 여과 농축한 다음 동결 또는 분무건조시킨 단삼추출물분말 10.0∼30.0 중량%, 갈근추출물분말 10.0∼20.0 중량%, 천궁추출물분말 1.0∼10.0 중량%, 홍화씨추출물분말 1.0∼10.0 중량%, 산사자추출물분말 5.0∼15.0 중량%와, 3) 제제학적으로 허용 가능한 1종이상의 담체를 혼합, 균질화 시켜 고지혈증용 건강 기능 식품조성물을 제조하는 방법.
1) Fingering mushroom (fruiting body) is extracted in an autoclave extractor with one solvent selected from water, ethanol or a mixture thereof at 110-130 ° C for 2-3 hours, concentrated by filtration, and then frozen or spray-dried. Mushroom extract powder 35.0 ~ 55.0% by weight and 2) Danshen, Ginger root, cnidium, safflower seed, and mountain lion at 110 ~ 130 ℃ for 2-3 hours, respectively, separately autoclaved with one solvent selected from water, ethanol or a mixture thereof Extracted in an extractor, concentrated by filtration, and then frozen or spray-dried, 10.0-30.0% by weight of Danshen extract powder, 10.0-20.0% by weight of radish root extract powder, 1.0-10.0% by weight of cnidium extract powder, 1.0-10.0% by weight of safflower seed extract powder, A method for preparing a health functional food composition for hyperlipidemia by mixing and homogenizing 5.0 to 15.0% by weight of hawthorn extract powder and 3) one or more pharmaceutically acceptable carriers.
KR1020210078578A 2021-06-17 2021-06-17 Health functional foods that prevent hyperlipidemia KR20220168723A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210078578A KR20220168723A (en) 2021-06-17 2021-06-17 Health functional foods that prevent hyperlipidemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020210078578A KR20220168723A (en) 2021-06-17 2021-06-17 Health functional foods that prevent hyperlipidemia

Publications (1)

Publication Number Publication Date
KR20220168723A true KR20220168723A (en) 2022-12-26

Family

ID=84547498

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210078578A KR20220168723A (en) 2021-06-17 2021-06-17 Health functional foods that prevent hyperlipidemia

Country Status (1)

Country Link
KR (1) KR20220168723A (en)

Similar Documents

Publication Publication Date Title
KR100793204B1 (en) Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient
JP7471393B2 (en) Tea composition having preventive or ameliorative effects on respiratory diseases and pharmaceutical composition containing the same
CN112336815A (en) Anti-aging composition for strengthening body, preventing cancer and conditioning hypertension, hyperglycemia and hyperlipidemia and application thereof
CN106389788B (en) It is a kind of for enhancing the drug extract, preparation and preparation method of immunologic function of livestock and birds and anti-virus ability
KR20000037814A (en) Healthy food contained natural medicine materials
KR102243873B1 (en) Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof
CN106581166A (en) Anti-fatigue food, health product or pharmaceutical composition
CN105943617A (en) Application of whole hemp extract in preparation of anti-hepatitis drugs
KR101987554B1 (en) Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata
KR101028073B1 (en) Natural herb medicine composition improving blood circulation and immune activity of human body and its process of production
KR100545407B1 (en) Food composition for the treatment of the hyperlipidemia and its process
KR20220168723A (en) Health functional foods that prevent hyperlipidemia
JP2004352626A (en) Anticholesterol agent containing plant-derived component
CN107812115A (en) A kind of Chinese medicine composition for treating diabetes
KR100505780B1 (en) Healthy food composition having efficacy of anti-diabetic and its process
KR100609643B1 (en) Herbal medicine composition for the treatment of dermatitis and a method of manufacturing the same
KR101953576B1 (en) Functional beverage for anticancer and process for preparing the same
CN103933472B (en) A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer
KR101337525B1 (en) The Pharmaceutical compositions for prevention or treatment of hepatitis B containing extracts and fractions of Phyllanthus urinaria L and Hovenia dulcis Thunberg and Scutellaria baicalensis G. and Cinnamon as an active ingredient
KR100642801B1 (en) Anti-diabetic food composition comprising extracts from natural herbal materials and pear and process for preparing the same
KR20140083493A (en) Composition for anti-obesity comprising extract of Sargassum fulvellum or Sargassum horneri as an effective component
RU2257221C1 (en) Helminthicide species
CN109985080B (en) Preparation method and application of double-layer tablet containing ginseng and acanthopanax sessiliflorus
KR102520686B1 (en) The health drink containing mainly Gastrodia elata Blume
KR101195447B1 (en) The composition of herb mixture for prevention and treatment of Diabetes mellitus